Acta Neuropathologica

, Volume 115, Issue 4, pp 479–489

Curcumin inhibits aggregation of α-synuclein

  • Neeraj Pandey
  • Jeffrey Strider
  • William C. Nolan
  • Sherry X. Yan
  • James E. Galvin
Original Paper


Aggregation of amyloid-beta protein (Aβ) is a key pathogenic event in Alzheimer’s disease (AD). Curcumin, a constituent of the Indian spice Turmeric is structurally similar to Congo Red and has been demonstrated to bind Aβ amyloid and prevent further oligomerization of Aβ monomers onto growing amyloid β-sheets. Reasoning that oligomerization kinetics and mechanism of amyloid formation are similar in Parkinson’s disease (PD) and AD, we investigated the effect of curcumin on α-synuclein (AS) protein aggregation. In vitro model of AS aggregation was developed by treatment of purified AS protein (wild-type) with 1 mM Fe3+ (Fenton reaction). It was observed that the addition of curcumin inhibited aggregation in a dose-dependent manner and increased AS solubility. The aggregation-inhibiting effect of curcumin was next investigated in cell culture utilizing catecholaminergic SH-SY5Y cell line. A model system was developed in which the red fluorescent protein (DsRed2) was fused with A53T mutant of AS and its aggregation examined under different concentrations of curcumin. To estimate aggregation in an unbiased manner, a protocol was developed in which the images were captured automatically through a high-throughput cell-based screening microscope. The obtained images were processed automatically for aggregates within a defined dimension of 1–6 μm. Greater than 32% decrease in mutant α-synuclein aggregation was observed within 48 h subsequent to curcumin addition. Our data suggest that curcumin inhibits AS oligomerization into higher molecular weight aggregates and therefore should be further explored as a potential therapeutic compound for PD and related disorders.


Alpha-synuclein Curcumin Parkinson’s disease Lewy bodies Amyloid Polyphenol 





Parkinson’s disease


Dementia with Lewy bodies


Alzheimer’s disease

Amyloid beta-protein

Supplementary material

401_2007_332_Fig6_ESM.jpg (3.3 mb)
Supplemental Fig. 1 (JPEG 3.27 MB)
401_2007_332_Fig7_ESM.jpg (2.9 mb)
Supplemental Fig. 2 (JPEG 2.89 MB)
401_2007_332_Fig8_ESM.jpg (1.7 mb)
Supplemental Fig. 3 (JPEG 1.71 MB)


  1. 1.
    Agbor GA, Oben JE, Ngogang JY, Xinxing C, Vinson JA (2005) Antioxidant capacity of some herbs/spices from cameroon: a comparative study of two methods. J Agric Food Chem 53:6819–6824PubMedCrossRefGoogle Scholar
  2. 2.
    Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–398PubMedGoogle Scholar
  3. 3.
    Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69:195–206PubMedGoogle Scholar
  4. 4.
    Ambegaokar SS, Wu L, Alamshahi K, Lau J, Jazayeri L, Chan S, Khanna P, Hsieh E, Timiras PS (2003) Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth. Neuro Endocrinol Lett 24:469–473PubMedGoogle Scholar
  5. 5.
    Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R (2002) Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta 1542:209–220PubMedCrossRefGoogle Scholar
  6. 6.
    Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis 6:367–377; discussion 443–9PubMedGoogle Scholar
  7. 7.
    Behari M, Bhatnagar SP, Muthane U, Deo D (2002) Experiences of Parkinson’s disease in India. Lancet Neurol 1:258–262PubMedCrossRefGoogle Scholar
  8. 8.
    Bevis BJ, Glick BS (2002) Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat Biotechnol 20:83–87PubMedCrossRefGoogle Scholar
  9. 9.
    Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J, Baron GS (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 77:5499–5502PubMedCrossRefGoogle Scholar
  10. 10.
    Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–2900PubMedGoogle Scholar
  11. 11.
    Choi HK, Won L, Roback JD, Wainer BH, Heller A (1992) Specific modulation of dopamine expression in neuronal hybrid cells by primary cells from different brain regions. Proc Natl Acad Sci USA 89:8943–8947PubMedCrossRefGoogle Scholar
  12. 12.
    Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA (2005) Prevention of Alzheimer’s disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26(Suppl 1):133–136PubMedCrossRefGoogle Scholar
  13. 13.
    Commandeur JN, Vermeulen NP (1996) Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26:667–680PubMedCrossRefGoogle Scholar
  14. 14.
    Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318–1320PubMedCrossRefGoogle Scholar
  15. 15.
    Conway KA, Harper JD, Lansbury PT Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39:2552–2263PubMedCrossRefGoogle Scholar
  16. 16.
    Craig WJ (1999) Health-promoting properties of common herbs. Am J Clin Nutr 70:491S–499SPubMedGoogle Scholar
  17. 17.
    Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22:110–114PubMedCrossRefGoogle Scholar
  18. 18.
    Eriksen JL, Dawson TM, Dickson DW, Petrucelli L (2003) Caught in the act: alpha-synuclein is the culprit in Parkinson’s disease. Neuron 40:453–456PubMedCrossRefGoogle Scholar
  19. 19.
    Frei B, Higdon JV (2003) Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133:3275S–3284SPubMedGoogle Scholar
  20. 20.
    Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ (2000) Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157:361–368PubMedGoogle Scholar
  21. 21.
    Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521–533PubMedCrossRefGoogle Scholar
  22. 22.
    Hasegawa T, Matsuzaki M, Takeda A, Kikuchi A, Akita H, Perry G, Smith MA, Itoyama Y (2004) Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res 1013:51–59PubMedCrossRefGoogle Scholar
  23. 23.
    Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10:717–721PubMedCrossRefGoogle Scholar
  24. 24.
    Jana NR, Tanaka M, Wang G, Nukina N (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 9:2009–2018PubMedCrossRefGoogle Scholar
  25. 25.
    Jana NR, Dikshit P, Goswami A, Nukina N (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279:11680–11685PubMedCrossRefGoogle Scholar
  26. 26.
    Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489PubMedCrossRefGoogle Scholar
  27. 27.
    Lau FC, Shukitt-Hale B, Joseph JA (2005) The beneficial effects of fruit polyphenols on brain aging. Neurobiol Aging 26(Suppl 1):128–132PubMedCrossRefGoogle Scholar
  28. 28.
    Lee CS, Tee LY, Warmke T, Vinjamoori A, Cai A, Fagan AM, Snider BJ (2004) A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 91:996–1006PubMedCrossRefGoogle Scholar
  29. 29.
    Lee HJ, Khoshaghideh F, Patel S, Lee SJ (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24:1888–1896PubMedCrossRefGoogle Scholar
  30. 30.
    Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382PubMedCrossRefGoogle Scholar
  31. 31.
    McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2:589–594PubMedCrossRefGoogle Scholar
  32. 32.
    McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13:1437–1441PubMedCrossRefGoogle Scholar
  33. 33.
    Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97:105–115PubMedCrossRefGoogle Scholar
  34. 34.
    Pandey N, Schmidt RE, Galvin JE (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 197:515–520PubMedCrossRefGoogle Scholar
  35. 35.
    Prasad JE, Kumar B, Andreatta C, Nahreini P, Hanson AJ, Yan XD, Prasad KN (2004) Overexpression of alpha-synuclein decreased viability and enhanced sensitivity to prostaglandin E(2), hydrogen peroxide, and a nitric oxide donor in differentiated neuroblastoma cells. J Neurosci Res 76:415–422PubMedCrossRefGoogle Scholar
  36. 36.
    Ragothaman M, Murgod UA, Gururaj G, Kumaraswamy SD, Muthane U (2003) Lower risk of Parkinson’s disease in an admixed population of European and Indian origins. Mov Disord 18:912–914PubMedCrossRefGoogle Scholar
  37. 37.
    Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D (2005) In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16:360–367PubMedCrossRefGoogle Scholar
  38. 38.
    Singh S, Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270:24995–25000PubMedCrossRefGoogle Scholar
  39. 39.
    Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M (2001) Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 65:432–438PubMedCrossRefGoogle Scholar
  40. 40.
    Venkatesan P, Rao MN (2000) Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J Pharm Pharmacol 52:1123–1128PubMedCrossRefGoogle Scholar
  41. 41.
    Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892–5901PubMedCrossRefGoogle Scholar
  42. 42.
    Yarbrough D, Wachter RM, Kallio K, Matz MV, Remington SJ (2001) Refined crystal structure of DsRed, a red fluorescent protein from coral, at 2.0-A resolution. Proc Natl Acad Sci USA 98:462–467PubMedCrossRefGoogle Scholar
  43. 43.
    Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 39:1119–1125PubMedCrossRefGoogle Scholar
  44. 44.
    Zhang X, Xie W, Qu S, Pan T, Wang X, Le W (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333:544–549PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Neeraj Pandey
    • 1
  • Jeffrey Strider
    • 2
  • William C. Nolan
    • 3
  • Sherry X. Yan
    • 4
  • James E. Galvin
    • 4
    • 5
    • 6
  1. 1.Department of Anatomy and NeurobiologyWashington University School of MedicineSt LouisUSA
  2. 2.Department of NeuropathologyWashington University School of MedicineSt LouisUSA
  3. 3.Department of Biochemistry and Molecular BiologyWashington University School of MedicineSt LouisUSA
  4. 4.Department of NeurologyWashington University School of MedicineSt LouisUSA
  5. 5.Department of PsychiatryWashington University School of MedicineSt LouisUSA
  6. 6.Alzheimer Disease Research Center, Department of NeurobiologyWashington University School of MedicineSt LouisUSA

Personalised recommendations